Coya Therapeutics (COYA) vs Gossamer Bio (GOSS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Coya Therapeutics (COYA) has outperformed Gossamer Bio (GOSS) over the past year, losing 50.7% versus a loss of 95.6%. Coya Therapeutics is the larger company by market cap ($69.2 million vs $65.6 million), about 1.1 times the size. Coya Therapeutics converts more of its revenue into profit, with a net margin of -267.1% versus -351.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COYA | GOSS |
|---|---|---|
| Share price | $2.95 | $10.72 |
| Market cap | $69.20M | $65.57M |
| 1-day change | -1.01% | -4.54% |
| YTD return | -49.14% | -95.68% |
| 1-year return | -50.67% | -95.62% |
| 5-year return | — | -98.74% |
| EPS (TTM) | $-1.39 | $-42.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.95M | $48.47M |
| Revenue growth (YoY) | +123.57% | -57.74% |
| Net income (latest FY) | $-21.23M | $-170.37M |
| Operating margin | -283.87% | -352.23% |
| Net margin | -267.14% | -351.49% |
| 52-week high | $6.62 | $309.60 |
| 52-week low | $2.72 | $8.29 |
| Distance from 52-week high | -55.44% | -96.54% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +415.59% | +669.40% |
| Average volume | 149.18K | 243.40K |
| Shares outstanding | 23.46M | 6.12M |
| Employees | 8 | 161 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COYA has outperformed GOSS by 45.0 percentage points over the past year.
- Coya Therapeutics is more profitable, keeping -267.1 cents of every revenue dollar as net income versus -351.5 cents for Gossamer Bio.
- Coya Therapeutics grew revenue faster in its latest fiscal year (+123.57% vs -57.74%).
About Coya Therapeutics
COYA stock →Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Gossamer Bio
GOSS stock →Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
COYA vs GOSS FAQ
Which is bigger, Coya Therapeutics or Gossamer Bio?
Coya Therapeutics (COYA) is larger, with a market capitalization of $69.20M compared with $65.57M for Gossamer Bio (GOSS).
Which stock has performed better over the past year, COYA or GOSS?
COYA returned -50.67% over the past 12 months, compared with -95.62% for GOSS (price return, excluding dividends). Past performance does not predict future results.
Are Coya Therapeutics and Gossamer Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.